Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer

Olaguoke Akinwande, Amanda Miller, David Hayes, Ryan O'hara, Dana Tomalty, Robert C.G. Martin

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Background: Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pretreated patients with metastatic colorectal cancer (CRC). Patients and Methods: An Institutional Review Boardapproved, multi-institutional registry from 5/2008 to 8/2013 was reviewed. Patients who received DEBIRI with (XDEBIRI) or without (DEBIRI) capecitabine were compared. Results: Twenty-two X-DEBIRI and 149 DEBIRI patients were compared. There was no difference in the two groups with regards to adverse events (p=0.56). During a 3- and 6- month evaluation, the disease control rate (DCR) was similar in both groups. During the 12-month evaluation, there was better DCR in the X-DEBIRI group (p=0.03). Median survival was 13 months in the DEBIRI group and 22 months in the X-DEBIRI group (log-rank test, p=0.217). Conclusion: There is no additional toxicity when adding capecitabine with DEBIRI. Concurrent capecitabine may offer more durable disease control rate compared to DEBIRI-alone. Survival benefit with concurrent capecitabine was not statistically significant but there may be a trend towards improved survival.

Original languageEnglish
Pages (from-to)7239-7245
Number of pages7
JournalAnticancer research
Issue number12
StatePublished - Dec 1 2014


  • Capecitabine
  • Chemoembolization
  • Drugeluting-beads
  • Irinotecan
  • Toxicity


Dive into the research topics of 'Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this